

line 8, after "~~X~~₁₈ is G" delete "or E", and

line 9, after "~~W~~ or" delete "K" and insert --E--.

Claim 12, line 2 delete "Gly498Glu" and

line 3, delete "Lys" and insert --Glu--.

Claim 19, line 1, delete "a method for".

Claim 21, line 3, delete "Gly498Glu, Arg/Trp499Lys" and insert --Arg/Trp499Glu--.

REMARKS

Reconsideration is requested.

The specification has been amended to include the attached Sequence Listing. The specification and claims have been amended to include sequence identifiers. No new matter has been added. The attached paper and computer readable copies of the Sequence Listing are the same. A separate Letter to this effect is attached.


The above amendments correct inadvertent typographical errors. Support for the amendment of "Arg/Trp499Glu" and the similar recitation "R/W499E" may be found, for example, in Figure 4 wherein amino acid number 499 is indicated as being R/W and page 7, lines 17-19, which describe, for example, the double mutation at bases 226 and 227 of SEQ ID NO: 17 to G and A. This double mutation produces a "Gly" or "E" at amino acid position 76 of SEQ ID NO: 17. The applicants note, for the Examiner's convenience, that the M (met) of the YMDD motif, such as is found spanning amino acids 126-129 of SEQ ID NO: 17, is amino acid 550 of HBV DNA polymerase. See, page 1, lines 27-28 of the specification. Amino acid 76 of SEQ ID NO: 17 therefore is amino acid 499, as indicated in the above amendments. No new matter has been added.

An early and favorable Action is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B.J. Sadoff
Reg. No. 36,663

BJS:rdw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4091
Facsimile: (703) 816-4100